{"product_id":"soliqua-insulina-glargina-lixisenatida-pluma-100ml-33mcg-con-1","title":"Soliqua (Insulin Glargine\/Lixisenatide) Pen 100ml\/33mcg With 1","description":"\u003ch2\u003eCategory\u003c\/h2\u003e\n\u003cp\u003eMedication\u003c\/p\u003e\n\n\u003ch2\u003eLine\u003c\/h2\u003e\n\u003cp\u003eCombined Insulin\u003c\/p\u003e\n\n\u003ch2\u003eBrand\u003c\/h2\u003e\n\u003cp\u003eSoliqua\u003c\/p\u003e\n\n\u003ch2\u003eMolecule\u003c\/h2\u003e\n\u003cp\u003eInsulin Glargine \/ Lixisenatide\u003c\/p\u003e\n\n\u003ch2\u003ePresentation\u003c\/h2\u003e\n\u003cp\u003ePen 100 mL \/ 33 mcg with 1\u003c\/p\u003e\n\n\u003ch2\u003eLaboratory\u003c\/h2\u003e\n\u003cp\u003eSanofi\u003c\/p\u003e\n\n\u003ch2\u003eIndications\u003c\/h2\u003e\n\u003cp\u003eSoliqua is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and adequate exercise to improve glycemic control. It is used in patients who have not achieved adequate control with metformin alone or in combination with other oral antidiabetic drugs. It can also be administered to patients requiring basal insulin treatment, allowing for an effective combination of insulin and a GLP-1 agonist to optimize blood glucose control. Patient selection should be made considering the efficacy and tolerability profile of previous treatment.\u003c\/p\u003e\n\n\u003ch2\u003eComposition\u003c\/h2\u003e\n\u003cp\u003eEach pen contains: 100 units of Insulin Glargine (equivalent to 100 IU\/mL) and 33 mcg of Lixisenatide.\u003c\/p\u003e\n\n\u003ch2\u003eContraindications\u003c\/h2\u003e\n\u003cp\u003eIt is contraindicated in patients with hypersensitivity to insulin glargine, lixisenatide, or any of the excipients. It should not be used in episodes of diabetic ketoacidosis. It is not suitable for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.\u003c\/p\u003e\n\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\n\u003cp\u003eCaution should be exercised in patients with a history of pancreatitis, as acute pancreatitis has been reported in some patients treated with GLP-1 agonists. The possibility of hypoglycemia should also be considered, especially in patients performing activities that may increase the risk of this condition. Regular monitoring of blood glucose levels is recommended.\u003c\/p\u003e\n\n\u003ch2\u003eStorage\u003c\/h2\u003e\n\u003cp\u003eStore refrigerated between 2 °C and 8 °C. Do not freeze. Once opened, the pen can be stored at room temperature (not above 30 °C) for a maximum of 28 days. Keep out of reach of children.\u003c\/p\u003e\n\n\u003cp\u003ePrescription required.\u003c\/p\u003e\n\u003cp\u003eConsult your doctor.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":46299584757985,"sku":"7501165011977","price":2744.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0722\/1500\/3361\/files\/planogram__1__cb9dc549-1194-4246-b339-07b29bc96781.jpg?v=1744713057","url":"https:\/\/wecarepharma.mx\/en\/products\/soliqua-insulina-glargina-lixisenatida-pluma-100ml-33mcg-con-1","provider":"WeCare Pharma","version":"1.0","type":"link"}